May 26, 2015

The Food and Drug Administration has approved Boehringer Ingelheim, Inc.'s Stiolto Respimat (tiotropium bromide and olodaterol), a once-daily inhaler meant to treat obstructed airflow in patients, the company announced Tuesday. 

January 21, 2015

Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States. 

 

September 26, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease. 

May 1, 2014

GlaxoSmithKline on Wednesday announced that the Food and Drug Administration approved Incruse Ellipta (umeclidinium), which is used for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and/or emphysema.

January 30, 2013

A panel of Food and Drug Administration experts has recommended approval for an experimental drug made by Boehringer Ingelheim for chronic obstructive pulmonary disease, the drug maker said.